ASH 2014: Highlights in multiple myeloma
ASH 2014: Highlights in multiple myeloma
New immunotherapy compound effective, safe in ALL patients with minimal residual disease
Checkpoint inhibitors show safety and efficacy in Hodgkin lymphoma
ASH 2014: Expert discussion on the latest in AML
Pembrolizumab may bring hope for patients with Hodgkin lymphoma
Immunology highlights from ASH 2014
Comment: T cell therapy for children with aggressive leukaemia
Comment: New PD-1 checkpoint inhibitors for treating Hodgkin lymphoma
ASH 2014: Expert discussion on the latest in CLL
Engineering stem cell resistance to HIV for two-pronged approach to HIV-associated lymphoma
Investigational antibody demonstrates efficacy, safety for patients with aggressive multiple myeloma in phase I study
HIV-associated lymphoma responds well to stem cell transplantation